* Preparations progress as planned
* Loan facilities provide support for 2025
* Our model suggests a fair value of SEK 16.29 per share
Lipum reported in its Q2 report that the manufacturing process of SOL-116 is nearing the final phase. The drug candidate is now being produced according to GMP standards, and the last batch is underway. At the same time, some of the company's major shareholders have provided short-term loans to finance the activities for the rest of the year. Shortly, we expect Lipum to announce a plan for financing the upcoming phase II study, which we now expect to start in Q2 2026.